Patients with a history of gallstones or biliary disease should discuss their individual risk profile with their prescribing clinician before starting treatment
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
The 250g bag already delivers substantially better value than the 100g option, while the 500g and 1kg sizes are among the least expensive ways to maintain a long-term NAC regimen
It is not for human or veterinary consumption, therapeutic use, or diagnostic procedures.
:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)
.png?sfvrsn=1e7191c0_3)
